Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it has reached an agreement with Memorial Sloan Kettering Cancer Center to develop and commercialize products and services that include assessment of tumor mutation burden (TMB) biomarker status.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.